Literature DB >> 20181950

Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype.

Asya L Borikova1, Christopher F Dibble, Noah Sciaky, Christopher M Welch, Amy N Abell, Sompop Bencharit, Gary L Johnson.   

Abstract

Cerebral cavernous malformations (CCM) are vascular lesions causing seizures and stroke. Mutations causing inactivation of one of three genes, ccm1, -2, or -3, are sufficient to induce vascular endothelial cell defects resulting in CCM. Herein, we show that loss of expression of the CCM1, -2, or -3 proteins causes a marked increase in expression of the GTPase RhoA. Live cell imaging with a RhoA-specific biosensor demonstrates increased RhoA activity with loss of CCM1, -2, or -3, with an especially pronounced RhoA activation in both the cytosol and the nucleus with loss of CCM1 expression. Increased RhoA activation was associated with Rho kinase-dependent phosphorylation of myosin light chain 2. Functionally, loss of CCM1, -2, or -3 inhibited endothelial cell vessel-like tube formation and extracellular matrix invasion, each of which is rescued by chemical inhibition or short hairpin RNA knockdown of Rho kinase. The findings, for the first time, define a signaling network for CCM1, -2, and -3 in CCM pathology, whereby loss of CCM1, -2, or -3 protein expression results in increased RhoA activity, with the activation of Rho kinase responsible for endothelial cell dysregulation. The results define Rho kinase as a therapeutic target to rescue endothelial cells from loss of CCM protein function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181950      PMCID: PMC2852911          DOI: 10.1074/jbc.C109.097220

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Rho GTPases: biochemistry and biology.

Authors:  Aron B Jaffe; Alan Hall
Journal:  Annu Rev Cell Dev Biol       Date:  2005       Impact factor: 13.827

Review 2.  Recent evidence for an involvement of rho-kinase in cerebral vascular disease.

Authors:  Sophocles Chrissobolis; Christopher G Sobey
Journal:  Stroke       Date:  2006-06-29       Impact factor: 7.914

3.  Spatiotemporal dynamics of RhoA activity in migrating cells.

Authors:  Olivier Pertz; Louis Hodgson; Richard L Klemke; Klaus M Hahn
Journal:  Nature       Date:  2006-03-19       Impact factor: 49.962

Review 4.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

Review 5.  Genetics of cerebral cavernous malformations.

Authors:  Nicholas W Plummer; Jon S Zawistowski; Douglas A Marchuk
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

6.  Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.

Authors:  Yoshio Suzuki; Masato Shibuya; Shin-ichi Satoh; Hirotoshi Sugiyama; Minoru Seto; Kintomo Takakura
Journal:  Neurol Med Chir (Tokyo)       Date:  2008-06       Impact factor: 1.742

7.  Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice.

Authors:  Sy Inan; K Büyükafşar
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

8.  Proteomic identification of the cerebral cavernous malformation signaling complex.

Authors:  Thomas L Hilder; Michael H Malone; Sompop Bencharit; John Colicelli; Timothy A Haystead; Gary L Johnson; Christine C Wu
Journal:  J Proteome Res       Date:  2007-09-27       Impact factor: 4.466

9.  The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases.

Authors:  Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

10.  Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway.

Authors:  Benjamin Kleaveland; Xiangjian Zheng; Jian J Liu; Yannick Blum; Jennifer J Tung; Zhiying Zou; Shawn M Sweeney; Mei Chen; Lili Guo; Min-min Lu; Diane Zhou; Jan Kitajewski; Markus Affolter; Mark H Ginsberg; Mark L Kahn
Journal:  Nat Med       Date:  2009-01-18       Impact factor: 53.440

View more
  69 in total

1.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

Review 2.  Evaluating strategies for the treatment of cerebral cavernous malformations.

Authors:  Dean Y Li; Kevin J Whitehead
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

3.  Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Authors:  Aubrey C Chan; Stavros G Drakos; Oscar E Ruiz; Alexandra C H Smith; Christopher C Gibson; Jing Ling; Samuel F Passi; Amber N Stratman; Anastasia Sacharidou; M Patricia Revelo; Allie H Grossmann; Nikolaos A Diakos; George E Davis; Mark M Metzstein; Kevin J Whitehead; Dean Y Li
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Structure-function analysis of core STRIPAK Proteins: a signaling complex implicated in Golgi polarization.

Authors:  Michelle J Kean; Derek F Ceccarelli; Marilyn Goudreault; Mario Sanches; Stephen Tate; Brett Larsen; Lucien C D Gibson; W Brent Derry; Ian C Scott; Laurence Pelletier; George S Baillie; Frank Sicheri; Anne-Claude Gingras
Journal:  J Biol Chem       Date:  2011-05-11       Impact factor: 5.157

5.  PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Authors:  Svetlana M Stamatovic; Nikola Sladojevic; Richard F Keep; Anuska V Andjelkovic
Journal:  Acta Neuropathol       Date:  2015-09-18       Impact factor: 17.088

Review 6.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

Review 7.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

8.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

9.  Cerebral Cavernous Malformations Develop Through Clonal Expansion of Mutant Endothelial Cells.

Authors:  Matthew R Detter; Daniel A Snellings; Douglas A Marchuk
Journal:  Circ Res       Date:  2018-10-26       Impact factor: 17.367

Review 10.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.